Imaavy receives FDA priority review for warm autoimmune hemolytic anemia

9 articles · Updated · MarketWatch · Apr 27

Johnson & Johnson announced the FDA granted priority review to Imaavy, also known as nipocalimab, following positive Phase 2/3 Energy study results.
This accelerated review could make Imaavy the first approved treatment for the rare and serious blood disorder, which destroys red blood cells.
Imaavy targets the underlying cause by reducing immunoglobulin G autoantibodies and is also being studied for multiple other auto- and alloantibody-driven diseases.

What specific trial data made the FDA fast-track Imaavy, setting a new bar for rare disease drugs?

As a new rare disease therapy, what will be the price tag for Imaavy's life-changing potential?

With rivals advancing, can J&J's Imaavy truly dominate the future warm autoimmune hemolytic anemia treatment market?

What long-term risks does systemically lowering all IgG antibodies with Imaavy pose to patients?

Is J&J's bet on Imaavy the key to reviving its immunology empire after its top drug's patent expires?

How soon could patients realistically access this groundbreaking treatment for a disease with no approved therapies?